{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:14:12Z","timestamp":1772579652804,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Immune-related thyroid adverse events (irTAEs) occur frequently following immune checkpoint inhibitor (ICI) therapy. The purpose of this study is to provide knowledge about the incidence, clinical timeline characteristics, associated factors of irTAEs, and potential impact on treatment efficacy in patients with melanoma receiving adjuvant ICI therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A national multicenter retrospective cohort study of patients with resected stage III\/IV melanoma treated with adjuvant PD-1 inhibitors between November 2018 and December 2020. Data were extracted from the Danish Metastatic Melanoma Database. The irTAEs were defined as two consecutive abnormal TSH values and subdivided into transient or persistent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 454 patients, 99 developed an irTAE (21.8%), of these were 46 transient (46.5%) and 53 persistent (53.5%). Median time to transient and persistent irTAE was 55 and 44\u00a0days, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.57). A hyperthyroid phase followed by hypothyroidism was seen in 73.6% of persistent irTAEs, whereas 87% of transient irTAEs developed an isolated hypo- or hyperthyroid phase. Multiple variable analysis demonstrated an association between irTAE and female sex (HR 2.45; 95% CI 1.63\u20133.70; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), but no association with recurrence-free survival (HR 0.86; 95% CI 0.50\u20131.48; <jats:italic>p<\/jats:italic>\u2009=\u20090.587) or overall survival (HR 1.05; 95% CI 0.52\u20132.12, <jats:italic>p<\/jats:italic>\u2009=\u20090.891).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IrTAE is a common side effect to PD-1 inhibitors primarily occurring within the first 3\u00a0months, with a high risk of persistency. Female sex is a strong predictive factor. IrTAE was not associated with improved clinical outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08445-y","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:02:00Z","timestamp":1712761320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III\/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study"],"prefix":"10.1007","volume":"32","author":[{"given":"Stine K.","family":"Christensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette L.","family":"Winther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida J.","family":"Laursen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freja S.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-1962","authenticated-orcid":false,"given":"Carsten","family":"Brink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-531X","authenticated-orcid":false,"given":"Thomas H.","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-9232","authenticated-orcid":false,"given":"Eva","family":"Ellebaek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederikke S.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Haslund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia K.","family":"Laursen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida D.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-273X","authenticated-orcid":false,"given":"Christina H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"8445_CR1","doi-asserted-by":"publisher","first-page":"976224","DOI":"10.3389\/fonc.2022.976224","volume":"12","author":"Q Sun","year":"2022","unstructured":"Sun Q, Sun H, Wu N et al (2022) Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: a systematic review and meta-analysis. Front Oncol 12:976224. https:\/\/doi.org\/10.3389\/fonc.2022.976224","journal-title":"Front Oncol"},{"key":"8445_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1089\/thy.2018.0116","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG et al (2018) Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid 28:1243\u20131251. https:\/\/doi.org\/10.1089\/thy.2018.0116","journal-title":"Thyroid"},{"key":"8445_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40487-019-0096-8","volume":"7","author":"LB Kennedy","year":"2019","unstructured":"Kennedy LB, Salama AKS (2019) A review of immune-mediated adverse events in melanoma. Oncol Ther 7:101\u2013120. https:\/\/doi.org\/10.1007\/s40487-019-0096-8","journal-title":"Oncol Ther"},{"key":"8445_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ et al (2017) Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev 58:70\u201376. https:\/\/doi.org\/10.1016\/j.ctrv.2017.06.002","journal-title":"Cancer Treat Rev"},{"key":"8445_CR5","doi-asserted-by":"publisher","first-page":"633032","DOI":"10.3389\/fonc.2021.633032","volume":"11","author":"Y Fan","year":"2021","unstructured":"Fan Y, Xie W, Huang H et al (2021) Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Front Oncol 11:633032. https:\/\/doi.org\/10.3389\/fonc.2021.633032","journal-title":"Front Oncol"},{"key":"8445_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6:38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"key":"8445_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu X, Shi Y, Zhang D et al (2021) Risk factors for immune-related adverse events: what have we learned and what lies ahead? Biomark Res 9:79. https:\/\/doi.org\/10.1186\/s40364-021-00314-8","journal-title":"Biomark Res"},{"key":"8445_CR8","doi-asserted-by":"publisher","first-page":"786046","DOI":"10.3389\/fimmu.2021.786046","volume":"12","author":"SK Wong","year":"2021","unstructured":"Wong SK, Nebhan CA, Johnson DB (2021) Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy. Front Immunol 12:786046. https:\/\/doi.org\/10.3389\/fimmu.2021.786046","journal-title":"Front Immunol"},{"key":"8445_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","volume":"9","author":"MA Socinski","year":"2023","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2023) Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol 9:527\u2013535. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7711","journal-title":"JAMA Oncol"},{"key":"8445_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B (2019) A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51:145\u2013156. https:\/\/doi.org\/10.1055\/a-0843-3366","journal-title":"Horm Metab Res"},{"key":"8445_CR11","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377\u20132385. https:\/\/doi.org\/10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"key":"8445_CR12","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1089\/thy.2020.0032","volume":"30","author":"CA Muir","year":"2020","unstructured":"Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM (2020) Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer. Thyroid 30:1458\u20131469. https:\/\/doi.org\/10.1089\/thy.2020.0032","journal-title":"Thyroid"},{"key":"8445_CR13","doi-asserted-by":"publisher","unstructured":"Dawidowska A, Jagodzinska-Mucha P, Kose\u0142a-Paterczyk H et al (2022) Immune-related thyroid adverse events predict response to PD-1 blockade in patients with melanoma Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14051248","DOI":"10.3390\/cancers14051248"},{"key":"8445_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","volume":"70","author":"J Lima Ferreira","year":"2021","unstructured":"Lima Ferreira J, Costa C, Marques B et al (2021) Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol Immunother 70:299\u2013309. https:\/\/doi.org\/10.1007\/s00262-020-02664-y","journal-title":"Cancer Immunol Immunother"},{"key":"8445_CR15","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","volume":"106","author":"CA Muir","year":"2021","unstructured":"Muir CA, Clifton-Bligh RJ, Long GV et al (2021) Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 106:e3704\u2013e3713. https:\/\/doi.org\/10.1210\/clinem\/dgab263","journal-title":"J Clin Endocrinol Metab"},{"key":"8445_CR16","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00262-022-03151-2","volume":"71","author":"MS von Itzstein","year":"2022","unstructured":"von Itzstein MS, Gonugunta AS, Wang Y et al (2022) Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 71:2169\u20132181. https:\/\/doi.org\/10.1007\/s00262-022-03151-2","journal-title":"Cancer Immunol Immunother"},{"key":"8445_CR17","doi-asserted-by":"publisher","first-page":"101943","DOI":"10.1016\/j.canep.2021.101943","volume":"73","author":"E Ellebaek","year":"2021","unstructured":"Ellebaek E, Svane IM, Schmidt H et al (2021) The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiol 73:101943. https:\/\/doi.org\/10.1016\/j.canep.2021.101943","journal-title":"Cancer Epidemiol"},{"key":"8445_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Kottschade L, Ryder M (2020) PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30:177\u2013184. https:\/\/doi.org\/10.1089\/thy.2019.0250","journal-title":"Thyroid"},{"key":"8445_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s12539-019-00337-8","volume":"11","author":"X Zhang","year":"2019","unstructured":"Zhang X, Wu Y, Lv J et al (2019) Nivolumab-induced thyroid dysfunctions in patients with previously treated non-small cell lung cancer. Interdiscip Sci 11:287\u2013291. https:\/\/doi.org\/10.1007\/s12539-019-00337-8","journal-title":"Interdiscip Sci"},{"key":"8445_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4158\/ep-2019-0244","volume":"26","author":"M Al Mushref","year":"2020","unstructured":"Al Mushref M, Guido PA, Collichio FA, Moore DT, Clemmons DR (2020) Thyroid dysfunction, recovery, and prognosis in melanoma patients treated with immune checkpoint inhibitors: a retrospective review. Endocr Pract 26:36\u201342. https:\/\/doi.org\/10.4158\/ep-2019-0244","journal-title":"Endocr Pract"},{"key":"8445_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"key":"8445_CR22","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE L\u00e9vesque","year":"2010","unstructured":"L\u00e9vesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. Bmj 340:b5087. https:\/\/doi.org\/10.1136\/bmj.b5087","journal-title":"Bmj"},{"key":"8445_CR23","doi-asserted-by":"publisher","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","volume":"14","author":"I Yamauchi","year":"2019","unstructured":"Yamauchi I, Yasoda A, Matsumoto S et al (2019) Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 14:e0216954. https:\/\/doi.org\/10.1371\/journal.pone.0216954","journal-title":"PLoS One"},{"key":"8445_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","volume":"6","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Kicinski M, Blank CU et al (2020) Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 6:519\u2013527. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5570","journal-title":"JAMA Oncol"},{"key":"8445_CR25","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bcp.14433","volume":"86","author":"BL Mangan","year":"2020","unstructured":"Mangan BL, McAlister RK, Balko JM et al (2020) Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. Br J Clin Pharmacol 86:1778\u20131789. https:\/\/doi.org\/10.1111\/bcp.14433","journal-title":"Br J Clin Pharmacol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08445-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:11:57Z","timestamp":1715591517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08445-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["8445"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08445-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"19 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data was extracted from DAMMED. This is a national platform for quality assurance and research in real-world data on medical therapy in Danish patients with melanoma. Informed consent was obtained from all participants included in the database. This study complied with the General Data Protection Regulation (GDPR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}